Teriparatide Trickles In For Richter

Forsteo Rival Posts Sales Of €4.8m Following Launches In August

Richter’s Terrosa biosimilar to Lilly’s Forsteo teriparatide brand made a modest start in Europe. But the Hungarian group still posted nine-month Pharmaceutical sales growth of 8.1%.

Coins
Gedeon Richter's Terrosa teriparatide brand has made a modest start in Europe • Source: Shutterstock

Launching its Terrosa (teriparatide) rival to Eli Lilly’s Forsteo blockbuster osteoporosis treatment in nine European countries following patent expiry on 19 August failed to make much of an impression on Gedeon Richter’s results in the first nine months of this year. Nevertheless, the Hungarian group was able to increase its Pharmaceutical turnover by 8.1% to €917.1m ($1.012bn) in the period.

Terrosa launches occurring from 20 August in the Hungarian firm’s domestic market, as well as in Austria, the Czech Republic,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin